Our Competence

Topical Formulation Development

Tergus Pharma is a One-Stop Solution for all of Your Topical Formulation Development Needs.

Know More

Manufacturing Facility

Tergus has a state-of-the-art semi-solid manufacturing facility and extensive expertise in the management and...

Know More

IVRT (Franz Diffusion)

Tergus Pharma provides significant expertise in In vitro Release Rate Test (IVRT) Method Development & Validation.

Know More

Skin Biology

Your API needs to reach its target and maintain efficacy, so skin penetration and permeation studies are a necessity.

Know More

As a CRO (Contract Research Organization), Tergus provides topical pharmaceutical R&D, testing and manufacturing services to companies of all sizes with agile and custom solutions. The industry experts in our team apply QbD (Quality by Design) principles to help you with formulation development, analysis, testing and clinical supply manufacturing. We excel in providing you with the best solution and take immense care in risk mitigation strategies.

Read More

Latest News

  • Dawn Slann joined Tergus effective June 11, 2018 in the capacity of Senior Director, Quality Assurance.
    June 13, 2018)
  • Tergus Announces Key Leadership Changes
    April 25, 2018)

Upcoming Events

  • Innovations in Dermatological Sciences Conference
  • CPhI
  • SAAM Meeting
  • AAPS Meeting
  • Derm Development Summit
Read More

Facebook Posts

7 days ago

Tergus Pharma

Successful meeting for Team Tergus at CPhI Worldwide meeting in Madrid. If you would like to speak with us here at CPhI, please send us an email at BusDev@TergusPharma.com #CphiWW @TergusPharma #Cphi #CPhIWorldwide #CPhI2018 ... See MoreSee Less

View on Facebook

7 days ago

Tergus Pharma

Tergus scientists will be attending the SAAMnow Annual Scientific Workshop (October 18-19, 2018). This inaugural workshop will address issues surrounding reverse engineering methods and strategies in the context of Q1/Q2/Q3 comparisons, with an eye toward reducing the clinical burden of generic drug development programs via BCS class 3 biowaivers, in vitro-only pathways for locally-acting and complex drug products, and, where biowaivers are not possible, streamlining complex human bioequivalence studies. We invite you to join the session and visit with our scientists. Drop us a line at busdev@terguspharma.com if you'd like to speak while at the meeting. saamnow.com #teamtergus #conferences Kevin Causey David Butners
Vijendra NALAMOTHU, Ph.D.
... See MoreSee Less

View on Facebook